Mouse Monoclonal Antibody to beta-Actin
Catalog No.：FA00195
【Specification】 Aliases : PS1TP5BP1; ACTB
Entrez GeneID : 60 clone : 8H10D10 WB Predicted band size : 42kDa Host/Isotype : Mouse IgG1 Antibody Type: Loading Control Antibody Storage: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. Species Reactivity: Human,Mouse,Hamster,Rat,Monkey,Dog Immunogen : Synthetic peptide corresponding to amino-terminal residues ofhuman beta-Actin, conjugated to KLH. Formulation: Purified antibody in PBS with 0.05% sodium azide. 【Description】
Beta-actin (PS1TP5-binding protein 1), also known as ACTB, PS1TP5BP1. EntrezProtein NP_001092. It is one of six different actin proteins. Actin, a ubiquitouseukaryotic protein, is the major component of the cytoskeleton.Actins are highlyconserved proteins that are involved in various types of cell motility, structure, andintegrity. Actin is ubiquitously expressed in all eukaryotic cells. This actin is a majorconstituent of the contractile apparatus and one of the two nonmuscle cytoskeletalactins. 【Application】
WB 1/10000 - 1/40000 IP 1/100-1/200 IF 1/50 - 1/500 FCM 1/200 - 1/400 ELISA 1/10000已验证抗体 * 退换有保障 For Research Only-Time Saved, Science Advanced 苏州丰度蛋白生物技术有限公司（www.fedprotein.com) Western blot analysis using beta-Actin mouse mAb against NIH/3T3 (1), Jurkat (2), Hela (3), CHO (4), PC12 (5), HEK293 (6), COS (7), A549 (8) and MCF-7 (9) cell lysate. Western blot analysis using beta-Actin mouse mAb against Rat serum(1),Rabbit serum(2),PC- 12(3),Raw264.7(4),NIH/3T3(5),NRK(6),C2C12(7) ,C6(8),L1210(9),F9(10),CHO3D10(11),Hela(12),J urkat(13) cell lysate. Immunoprecipitation using beta-Actin mouse mAb(dilution: 1/250) against HL- 60,C2C12,NRK,RSC,Hela,Cos7 cell lysate. Confocal Immunofluorescence analysis of SKBR-3 (left) and A549 (right) cells using beta Actin mouse mAb (red, the secondary Ab is Cy3-Goat anti mouse IgG). Blue: DRAQ5 fluorescent DNA dye. Flow cytometric analysis of MCF-7 cells using beta Actin mouse mAb (right) and negative control (left).
